Chlorpyrifos has undergone dramatic changes in its market trajectory, from a blockbuster proprietary molecule to a globally traded generic active ingredient. AgriBusiness Global spoke with Ram ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...

Google today released its 2025 Year in Search list, but don’t mistake it for a ranking of the “top searches” or the “most searched” terms. This year’s recap focused on trending queries – the topics ...

After primarily focusing on private conversations since its founding, Snapchat is embracing public conversations with a new “Topic Chats” feature. The social network says the feature lets users chat ...

The fun part about a programming language like C is that although the language doesn’t directly support many features including object-oriented programming and generics, there’s nothing that’s keeping ...

A few years ago, a leading U.S. hospital system rolled out a predictive AI model for patient readmissions. It had all the right components: a large training dataset, modern architecture and a ...

A terminal-based university course registration system built in Java, applying robust OOP principles and supporting roles like Students, Professors, Admins, and Teaching Assistants. Includes GPA ...

Out Of Order is a Java-based interactive game designed to test and improve the player's cognitive abilities. In this game, players are presented with a sequence of characters or numbers that are out ...

Teva Pharmaceutical Industries Limited has successfully shifted its strategy, leveraging its generics business to fund growth in specialty medicines, driving a turnaround in performance. TEVA's "Pivot ...

Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...